Griffiths, Ulla Kou; Bozzani, Fiammetta Maria; Chansa, Collins; Kinghorn, Anthony; Kalesha-Masumbu, Penelope; Rudd, Cheryl; Chilengi, Roma; Brenzel, Logan; Schutte, Carl; (2016) Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian immunisation programme: Are expansions sustainable? Vaccine, 34 (35). pp. 4213-4220. ISSN 0264-410X
DOI: https://doi.org/10.1016/j.vaccine.2016.06.050

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/2572557/

DOI: https://doi.org/10.1016/j.vaccine.2016.06.050

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian immunisation programme: Are expansions sustainable?

Ulla Kou Griffiths, Fiammetta Maria Bozzani, Collins Chansa, Anthony Kinghorn, Penelope Kalesha-Masumbue, Cheryl Rudd, Roma Chilenge, Logan Brenzel, Carl Schutte

Department of Global Health and Development, London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, United Kingdom
Strategic Development Consulting (SDC), Pietermaritzburg, South Africa
Perinatal Health Research Unit, University of the Witwatersrand, Chris Hani Baragwanath Hospital, Soweto, South Africa
World Bank, Zambia Country Office, Banc ABC House, Church Road, Lusaka, Zambia
World Health Organization, Lusaka, Zambia
Center for Infectious Disease Research in Zambia (CIDRZ), Plot 5032 Great North Road, Lusaka, Zambia
Bill and Melinda Gates Foundation, 1300 I Street, NW Suite 200, Washington, DC, United States

Article info
Article history:
Received 16 March 2016
Received in revised form 13 June 2016
Accepted 14 June 2016
Available online 28 June 2016

Keywords:
Gavi
Vaccines
Financing
Affordability
Costs

Abstract
Background: Introduction of new vaccines in low- and lower-middle-income countries has accelerated since Gavi, the Vaccine Alliance was established in 2000. This study sought to (i) estimate the costs of introducing pneumococcal conjugate vaccine, rotavirus vaccine and a second dose of measles vaccine in Zambia; and (ii) assess affordability of the new vaccines in relation to Gavi’s co-financing and eligibility policies.

Methods: Data on ‘one-time’ costs of cold storage expansions, training and social mobilisation were collected from the government and development partners. A detailed economic cost study of routine immunisation based on a representative sample of 51 health facilities provided information on labour and vaccine transport costs. Gavi co-financing payments and immunisation programme costs were projected until 2022 when Zambia is expected to transition from Gavi support. The ability of Zambia to self-finance both new and traditional vaccines was assessed by comparing these with projected government health expenditures.

Results: ‘One-time’ costs of introducing the three vaccines amounted to US$ 0.28 per capita. The new vaccines increased annual immunisation programme costs by 38%, resulting in economic cost per fully immunised child of US$ 102. Co-financing payments on average increased by 10% during 2008–2017, but must increase 49% annually between 2017 and 2022. In 2014, the government spent approximately 6% of its health expenditures on immunisation. Assuming no real budget increases, immunisation would account for around 10% in 2022. Vaccines represented 1% of government, non-personnel expenditures for health in 2014, and would be 6% in 2022, assuming no real budget increases.

Conclusion: While the introduction of new vaccines is justified by expected positive health impacts, long-term affordability will be challenging in light of the current economic climate in Zambia. The government needs to both allocate more resources to the health sector and seek efficiency gains within service provision.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Gavi, the Vaccine Alliance was founded in 2000 and is now the largest external funding source for vaccines in low- and lower-middle-income countries [1]. Introducing new vaccines requires substantial investments, not only in vaccine supplies, but also in ‘systems costs’, such as cold chain expansions [2,3]. Cost estimates of new vaccine introduction are vital both to Gavi and to recipient countries [4].

Zambia has introduced four new vaccines with Gavi support. The combined diphtheria-tetanus-pertussis (DTP)-Haemophilus
Influenza type B (Hib) vaccine was introduced in 2004. This was switched to DTP-hepatitis B-Hib (‘pentavalent’) vaccine in 2005. In 2009, a proposal was submitted for pneumococcal conjugate vaccine (PCV), rotavirus vaccine (RV) and a second dose of measles (MSD). Gavi approved PCV and MSD in 2010 and RV in 2011, following evidence of plans for cold chain expansions. However, PCV and MSD were only introduced in July 2013 and RV in November 2013. Delays were due to a measles outbreak in 2012, relocation of the Child Health Unit from the Ministry of Health to the new Ministry of Community Development, Mother and Child Health in 2011, delays in receiving the Gavi vaccine introduction grant, and delays in disbursements to sub-national levels [5].

A comprehensive study on the economic and fiscal costs of Zambia’s routine immunisation services was undertaken in 2012–13, before introduction of the three new vaccines [6]. This was part of the multi-country ‘Expanded Programme on Immunisation Costing (EPIC)’ studies, which used a common, ingredients-based costing approach [7]. The study found that average costs per vaccine dose delivered totalled US$ 7.18, with markedly higher unit costs in rural than urban facilities.

Our study objectives were to estimate the incremental costs of introducing PCV, MSD and RV and evaluate affordability after cessation of Gavi support. Although ‘one-time’ vaccine introduction costs were calculated, the primary objective was to examine the longer-term economic costs.

1.1. Gavi eligibility criteria and co-financing policy

Gavi’s current eligibility criteria, established in 2011, is Gross National Income (GNI) per capita of less than US$ 1500, which is adjusted annually for inflation to remain constant in real terms. In 2015, the threshold was US$ 1580 [8]. If GNI per capita increases above the threshold, the recipient country starts transitioning out of support [1].

Gavi’s co-financing policy requires countries to co-procure a portion of their new vaccines and injection equipment. MSD is exempted from co-financing, but after five years countries must take on the full costs [9]. Countries are divided into groups according to GNI per capita, which serves as a proxy for ability to pay [10] (Table 1). The trajectory towards self-financing is achieved by annual increases in co-financing levels in the highest income groups. The ability of countries to shoulder the increasing financing requirements has been questioned and shown to vary substantially [11,12].

### Table 1

Gavi co-financing policies 2008–2017.

| Country groups                        | 2008–2011                     | 2012–2016                     | 2017–2020                       |
|---------------------------------------|-------------------------------|-------------------------------|--------------------------------|
| Initial co-financing levels per vaccine dose |                               |                               |                                |
| 1. Low-income                        | 1.00                          | 1.00                          | 1.00                           |
| 2. Intermediate                      | 0.80                          | 0.80                          | 0.80                           |
| 3. Graduating                        | 0.60                          | 0.60                          | 0.60                           |
| 4. Least poor                        | 0.30                          | 0.30                          | 0.30                           |
| Initial co-financing levels per vaccine dose |                               |                               |                                |
| Fragile                               | US$ 0.01–US$ 0.30             | US$ 0.20                      | US$ 0.20                       |
| Least poor                            | Amounts differed for first    |                               |                                |
|                                      | and subsequent approved doses |                               |                                |
| Annual increase in co-financing per dose |                               |                               |                                |
| 15% for the least poor group          | 15% for the intermediate      | 15% for the preparatory        |
| Trajectory for transitioning out of support | group                        | transition group              |                                |
| Co-financing linked to vaccine price  | None specified                | Graduating group:             | Accelerated transition group:  |
|                                      |                                | • Linear increase to reach     | • Linear increase to reach     |
|                                      |                                | full vaccine price after 5     | full vaccine price after 5     |
|                                      |                                | years                          | years                          |
|                                      |                                | Graduating group:             | Preparatory transition group:  |
|                                      |                                | • Paying linearly towards     | • Paying linearly towards      |
|                                      |                                | full vaccine price             | full vaccine price             |

2. Methods

2.1. Incremental, economic costs of vaccine introductions

Economic costs were estimated in 2014 values, using an exchange rate of 6.18 Zambian Kwacha for one US$ [13] and adjusting earlier data by the Zambian Gross Domestic Product (GDP) deflator [14]. Economic costs were divided into ‘one-time’ and recurring. ‘One-time’ costs were expenditures specifically undertaken in preparation for the new vaccine introductions. Recurring costs were those that occur annually in the future. Capital costs were annualised using a 3% discount rate [15], but also presented without annualisation to show needed up-front expenditures.

The number of fully immunised children was approximated by the number reported to receive three doses of pentavalent vaccine (penta3). With 602,000 surviving infants and 86% penta3 coverage in 2014, this was 517,720 children [16]. Costs per capita were estimated using a 2014 population of 15,023,315 [17].

2.1.1. Vaccine and injection supplies

Vaccine costs were calculated by multiplying price per dose, coverage rate of the first dose, target population size, number of doses per child in the schedule and the vaccine wastage factor [18]. UNICEF 2014 vaccine dose prices were US$ 2.10 for RV, US$ 0.252 for MSD and US$ 7.00/3.50 for PCV [19]. According to the Advance Market Commitment for PCV, a certain quantity of doses is purchased for US$ 7.00 per dose and the remaining at the “tail price” of US$ 3.50 [20]. Since co-financing calculations are based on the tail price and as this will be the price Zambia will pay after Gavi transition, we used this price [21]. Freight charges for importing vaccines were 3%, 5% and 14% of the procurement value for PCV, RV and MSD, respectively [9]. 2014 vaccine coverage rates of the first doses of PCV and RV were assumed similar to DTP1 at 96% while coverage of MSD was 33% [16]. Vaccine wastage rates were assumed as 5% for both PCV and RV and 40% for MSD [22].

2.1.2. Cold storage equipment

Cold storage expansions were undertaken at national, provincial, district and health facility levels [23]. Several development partners contributed to this investment [2]. A proportion of the investments was allocated to the three new vaccines based on their relative packed volumes in the new schedule; 4.8 cm³ per dose for PCV, 17.1 cm³ for RV and 2.13 cm³ for measles [19,24]. The WHO vaccine volume calculator showed that the new vaccines increased the required volume by 70%, from 81.3 cm³ to 138 cm³ per penta3.
The new vaccines occupied 41% of total vaccine volume; PCV took up 11%, RV 25% and MSD 5%.

Power consumption for equipment was collected from WHO Product Information Sheets [26]. A unit price of US$ 0.089 per kilowatt per hour was obtained from ZESCO, the parastatal electricity company. Annual maintenance costs of cold storage equipment were estimated as 10% of the purchase price, based on a UNICEF maintenance grant.

2.1.3. Transport

The EPIC study found that annualised costs of vehicles, vehicle maintenance and fuel comprised 12.5% of total immunisation programme costs, amounting to US$ 4.435 million in 2014 values, or US$ 8.39 per penta3 child [6]. Vaccine delivery comprised a weighted average of 31% of total transport costs (35% in rural and 13% in urban facilities). Hence, vaccine transport costs amounted to US$ 2.60 per penta3 child. We increased the vaccine transport costs by 70%, in line with the increased vaccine volumes (43% due to RV; 18% to PCV; 9% to MSD), amounting to an incremental cost per penta3 child of US$ 1.82.

2.1.4. Training, social mobilisation and communications

As PCV and MSD were introduced concurrently, training and social mobilisation were done at the same time. Based on advice from key informants, we allocated 80% of these costs to PCV and 20% to MSD. Costs were annualised over two years, reflecting the usual frequency of training.

New vaccination cards and health facility registers were printed, the Health Management Information System was modified, and a post introduction evaluation was conducted in July 2014 [27]. These costs were equally distributed between the three vaccines. For PCV, temperature monitoring log sheets and stickers instructing health workers to dispose of unused, opened vials were applied to health facility refrigerators. These investments were all annualised using a useful life of ten years.

2.1.5. Human resources

Introduction of new vaccines did not lead to additional employments, but staff opportunity costs need to be accounted for. In the EPIC study, clinical staff at 51 randomly selected health facilities in nine districts were asked to allocate their working hours among all activities during one month [6]. Costs per dose delivered were estimated by dividing staff immunisation costs by number of vaccine doses delivered per year. Weighted average staff cost per dose was US$ 1.77, ranging from US$ 0.96 in urban to US$ 4.59 in rural facilities [6].

The EPIC study took place before introduction of the new vaccines, but facility staff were asked if they thought introductions would impact operating costs, and 73% responded that they did not think so [6]. However, in the Post Introduction Survey, 17 out of 26 health workers said that the new vaccines had increased their workload [27]. In the absence of time-motion studies, we allocated half of the EPIC study staff cost per dose to RV and PCV (US$ 0.885), as these are delivered at the same time as pentavalent vaccine. However, as MSD requires an additional visit at 18 months, we allocated the full economic cost of US$ 1.77 to each MSD dose delivered [6].

2.2. Affordability of Gavi supported vaccines

Zambia’s co-financing contributions were provided by the Gavi secretariat, and the Gavi website gave values of its vaccine and injection supplies donations [28]. Predictions of GNI per capita were used to determine when Zambia enters the accelerated transition phase [29]. Future co-financing amounts were calculated by assuming constant prices per dose of all four Gavi supported vaccines and using data from the United Nations Population Division to predict numbers of surviving infants [30]. Vaccination coverage was assumed constant for PCV and RV, and assumed to increase by 5% per year for MSD. Future costs of the remaining vaccines in the schedule were estimated similarly.

Total government immunisation programme costs were the sum of systems costs, procurement of traditional vaccines and injection supplies, and government expenditure to co-procure vaccines for Gavi co-financing. The EPIC study found that immunisation systems costs amounted to US$ 31.8 million in 2011, equivalent to US$ 61 per penta3 child [6]. Government immunisation costs for 2014 and beyond were determined by adding the incremental systems costs of the new vaccine introductions to this estimate and increasing costs in proportion with the rising birth cohort and, for MSD, also increased coverage.

When assessing affordability, we compared immunisation programme costs with total government health expenditures. For 2008–2014, government health expenditures were collected from the Accountant General’s Office [31]. For 2015, the health sector budget was used, and for 2016 and 2017, the mid-term expenditure framework Green Paper [32,33]. As the Zambian government considers staff costs fixed, we used government health expenditures excluding personnel costs when evaluating the affordability of vaccines only.

For 2018–2022, we assumed a nominal growth in health care expenditures of 10% per year, which was the average increase during 2014–2016, and equivalent to 5% real, annual increase with predicted inflation rates of around 5% [29]. We also considered a scenario assuming 0% real increase in annual health expenditures.

3. Results

3.1. Incremental costs of new vaccine introductions

3.1.1. Financial costs

‘One-time’, non-annualised, incremental costs amounted to US$ 4.21 million, equivalent to costs per infant in the birth cohort of US

| Table 2                                                                 |
|-------------------------------------------------|
| Financial costs of new vaccine introduction in Zambia (2014 US$).       |
| MSD | PCV | RV  | Total | Percent of total |
|-----------------|------|-----|-------|------------------|
| Cold storage investments | 228,515 | 505,663 | 1,207,044 | 1,941,223 |
| Social mobilisation   | 60,962  | 243,849 | 377,190  | 682,001 |
| Training             | 40,398  | 161,591 | 386,824  | 588,813 |
| Tally sheets and under-5 cards | 157,773 | 157,773 | 157,773  | 473,320 |
| Post introduction evaluation | 94,778  | 94,778  | 94,778   | 284,335 |
| Monitoring tools      | 32,876  | 131,505 | 76,918   | 241,300 |
| **Total**             | **615,304** | **1,295,161** | **2,300,528** | **4,210,992** |
| Costs per infant in birth cohort | 0.96 | 2.02 | 3.58 | 6.56 |
| Costs per capita      | 0.04 | 0.09 | 0.15 | 0.28 |

MSD: Measles second dose, PCV: Pneumococcal conjugate vaccine, RV: Rotavirus vaccine.
Cold storage rehabilitation and expansion totalled US$ 4.73 million, of which US$ 3.04 million was spent on health facility refrigerators and US$ 1.20 million on national and provincial walk-in cold rooms. Based on the volume estimates, US$ 1.94 million of the total was allocated to the three new vaccines (Table 2). Cold storage investments accounted for 46% of total 'one-time' costs while social mobilisation and training accounted for 16% and 14%, respectively.

Cold storage expansions were financed by JICA (36%), ELMA Foundation (34%), Zambian government (10%), Canadian International Development Agency (9%), ARK (7%), WHO (4%), and Boston University (0.3%). Gavi, through the vaccine introduction grant, funded 64% of the social mobilisation, training and monitoring activities. The remainder was paid by the government (29%), GSK (3%), WHO (3%) and Absolute Returns for Kids (1%).

### 3.1.2. Annualised incremental costs

Annual costs of vaccines and injection equipment increased from US$ 6.8 million to US$ 7.0 million after introduction of MSD, to US$ 14.0 million after PCV, and to US$ 16.9 million after RV (Table 3). Compared to the old schedule, the corresponding increases in vaccine costs were 2% after MSD, 147% after PCV and 147% after all three vaccines were introduced. Vaccine costs per penta3 child were US$ 13 under the old schedule and US$ 33 after the three new vaccine introductions.

When 'one-time' costs were annualised, training and social mobilisation were the most important capital costs, each comprising 2% of total costs (Table 4). Cold storage investment only comprised 1% of total vaccine introduction costs after annualisation. The 70% increase in vaccine volume caused extra vaccine transport costs of US$ 941,715 per year. Incremental staff time opportunity costs were US$ 351,628 for MSD, US$ 1.38 million for PCV, and US$ 900,381 for RV.

The EPIC study concluded that economic costs of routine immunisation in Zambia totalled US$ 38.2 million in 2011, equivalent to US$ 66 per penta3 child [6]. The three new vaccines increased total economic costs by an estimated 38% to US$ 52.9 million in 2014, corresponding to US$ 102 per penta3 child. Incremental, annual systems costs of introducing the three new vaccines were US$ 4.9 million, equivalent to US$ 7.69 per child in the birth cohort and US$ 0.31 per capita. The systems costs per vaccine dose administered were US$ 1.33 for PCV, US$ 2.15 for RV and US$ 3.43 for MSD.

### Table 3

| Antigen Doses per person | Vaccine coverage of first dose | Vial size | Wastage in percent | Costs per dose (incl. freight) | Total vaccine costs | Injection supply costs | Total costs % of total |
|--------------------------|-------------------------------|-----------|--------------------|-------------------------------|---------------------|------------------------|------------------------|
| Bacille Calmette Guerin | 1                             | 95%       | 20                 | 50%                           | 0.15                | 185,495                | 52,669                 | 238,164               | 1%                     |
| Diphtheria-Tetanus-       | 3                             | 96%       | 1                  | 5%                            | 2.87                | 5,242,890              | –                      | 5,365,205             | 32%                    |
| Pertussis-HepB-Hib       |                               |           |                    |                               |                     |                        |                        |                        |                        |
| Measles                  | 1                             | 85%       | 10                 | 40%                           | 0.29                | 245,002                | 40,073                 | 285,075               | 2%                     |
| Oral polio vaccine       | 4                             | 96%       | 10                 | 25%                           | 0.23                | 701,364                | –                      | 701,364               | 4%                     |
| Tetanus toxoid           | 2                             | 74%       | 10                 | 25%                           | 0.12                | 172,084                | 77,881                 | 249,966               | 1%                     |
| **Total before new vaccines** | | | | | | **6,546,835** | **290,937** | **6,837,773** |
| Measles 2nd dose         | 1                             | 33%       | 10                 | 40%                           | 0.29                | 97,564                 | 15,558                 | 113,122               | 1%                     |
| Pneumococcal conjugate   | 3                             | 96%       | 2                  | 5%                            | 3.61                | 6,766,366              | 120,314                | 7,886,680             | 42%                    |
| Rotavirus                | 2                             | 96%       | 1                  | 5%                            | 2.21                | 2,757,647              | –                      | 2,832,528             | 17%                    |
| **Total with new vaccines** | | | | | | **16,168,412** | **411,252** | **16,579,664** |

### Table 4

| Annualised one-time costs: | Measles 2nd dose | Pneumococcal | Rotavirus | Total |
|----------------------------|-----------------|--------------|-----------|-------|
| Training                   | 21,112          | 84,449       | 202,158   | 307,720 |
| Social mobilisation        | 21,552          | 107,760      | 133,348   | 262,660 |
| Cold storage investments   | 25,900          | 55,592       | 132,702   | 214,194 |
| Tally sheets and under-5 cards | 55,778       | 55,778       | 55,778    | 167,323 |
| Monitoring tools           | 23,603          | 58,114       | 27,193    | 108,909 |
| Post introduction evaluation | 33,507        | 33,507       | 33,507    | 100,521 |
| **Sub total**              | **181,451**     | **395,200**  | **584,686**| **1,161,337** |
| **Recurring costs:**       |                 |              |           |       |
| Vaccines                   | 97,564          | 6,766,366    | 2,275,647 | 9,621,577 |
| Human resources            | 351,628         | 1,382,538    | 900,381   | 2,634,548 |
| Vaccine transport          | 124,758         | 241,200      | 575,757   | 941,715 |
| Cold storage               | 23,248          | 52,172       | 124,538   | 199,958 |
| Injection supplies         | 15,558          | 120,314      | –         | 135,872 |
| **Sub total**              | **612,755**     | **8,562,591**| **4,358,323**| **13,533,670** |
| **Total annualised costs** | **794,206**     | **8,957,792**| **4,941,009**| **14,895,007** |

2014 reported last dose coverage 33% 77% 73% NA
Children reached with last dose 198,660 463,540 439,460 NA
Cost per child reached with last dose 4.00 19.32 11.25 NA
Costs per dose delivered 4.00 5.17 4.28 NA
Costs per infant in birth cohort 1.24 7.70 22.89
Costs per capita 0.05 0.60 0.33 0.98
3.2. Affordability

3.2.1. Co-financing of new vaccines

Zambia introduced pentavalent vaccine in 2005. Gavi’s first co-financing policy required countries to start co-procuring six years after introducing the first new vaccine; thus 2011 for Zambia. With GNI per capita of US$ 490 in 2005, Zambia belonged to the poorest co-financing country group, entailing flat levels of US$ 0.20 per dose for the first vaccine [10]. However, Zambia started voluntary co-financing in 2008 and paid US$ 0.82, US$ 0.92, US$ 0.30 and US$ 0.35 per dose of pentavalent vaccine during 2008–2011, respectively. This meant that the government procured 17% of pentavalent vaccines during those four years.

When Gavi’s second co-financing policy came into effect in 2012, Zambia’s GNI had increased to US$ 1,650 per capita, placing it in the intermediate group, requiring a 15% annual increase in the per dose amount. During 2012, Zambia procured the equivalent of US$ 0.27 per dose in co-financing for pentavalent vaccine and US$ 0.20 for PCV. During 2013, co-financing of RV was added, starting at US$ 0.20 per dose. During 2015, approximately 12% of pentavalent vaccines, 8% of PCV and 8% of RV were co-financed.

Gavi’s new co-financing policy starts in 2016, but the first year is a grace year with the old policy still applying. Zambia is in the accelerated transition group, as its GNI per capita has exceeded the Gavi eligibility threshold for three consecutive years (US$ 1650 in 2012, US$ 1700 in 2013 and US$ 1680 in 2014). Hence, Zambia is predicted to fully finance all vaccines in 2022.

Fig. 1 shows historical and predicted co-financing for the four new vaccines. Co-financing was US$ 1.7 million in 2015 and will increase to the full costs of the vaccines of US$ 18.3 million in 2022. While co-financing on average increased by 10% per year during 2008–2017, it needs to increase by an annual average of 49% between 2017 and 2022. During 2008–2021, vaccines totalling US$ 54.5 million will need to be co-procured, with pentavalent vaccine comprising 42%, PCV 39%, RV 16% and MSD 2%. Total vaccine costs according to financing source between 2008 and 2022 are included in Table A1 in supplementary material.

3.2.2. Affordability assessment

During 2008–2016, per capita government health expenditures fluctuated between US$ 14 in 2009 and US$ 45 in 2013 (Fig. 2).

Between 2009 and 2014, the government increased its real health expenditures (in Kwacha) by an average of 27% per year, but in 2014 and 2015 there was a real decrease of 1% and 2%, respectively. Dramatic depreciation of the Kwacha against the US$ in 2014 and 2015 made this equivalent to decreases of 9% and 23% in US$ terms, respectively. Personnel comprised between 42% and 58% of the government health budgets between 2011–2017. In 2014, government health expenditures inclusive and exclusive of personnel totalled US$ 690 million and US$ 297 million, respectively.

Routine immunisation programme costs were US$ 52.9 million in 2014, equivalent to 0.2% of GDP. Gavi funded approximately 20% of these costs. Immuisation programme expenditures paid for by the government comprised approximately 6% of government health expenditures. Vaccine expenditures comprised 1% of government health expenditures excluding personnel (Fig. 3). Per capita immunisation programme costs were US$ 2.36 in 2011, US$ 2.54 in 2014 and projected as US$ 2.91 in 2022. Government funded vaccine and injection equipment costs per capita will increase from US$ 0.14 in 2011 to US$ 1.00 in 2022. Assuming a 5% annual, inflation-adjusted increase in government health expenditures during 2017–2022, immunisation programme costs are projected to be 5% of total health expenditures in 2022. When assuming 0% increase in government health expenditures, immunisation costs would account for 10% in 2022.

Considering vaccine costs alone and assuming 5% real increase in government health expenditures, these will account for 3% in 2022 exclusive personnel. When assuming 0% annual increase until 2022, the proportion is 6%. For vaccine costs to remain at 1% of government health expenditures, excluding human resources, the nominal budget needs to increase by 30% each year between 2017 and 2022.

4. Discussion

Incremental, annual systems costs of introducing the three new vaccines were US$ 4.9 million, equivalent to US$ 7.69 per child in the birth cohort and US$ 0.31 per capita. With a total of 2.8 million doses delivered, the systems costs per vaccine dose delivered of all three vaccines were US$ 1.78. The systems costs were US$ 1.33 for PCV, US$ 2.15 for RV and US$ 3.43 for MSD. Costs of simultaneous introduction of PCV, RV and MSD in Ghana in 2012 totalled US$
2.42 per dose [34]. As this analysis was part of the EPIC studies, the methodology was quite similar to the present Zambia study and differences are likely due to distinct levels of unit costs between the two countries. A study in Gambia found incremental systems costs of PCV introduction of US$ 1.90 [35]. The higher costs in Gambia could be because this was not part of a simultaneous introduction. A study in Rwanda found economic systems costs of introducing PCV and RV of US$ 0.68 and US$ 0.54 per dose, respectively [36]. The higher costs in Zambia than Rwanda are especially due to differences in methods for estimating staff costs. While our estimate was based on economic costing of a sample of health facilities by the EPIC study, the Rwanda study assumed that it took six minutes to deliver a dose of vaccine, based on program manager information.

When including costs of vaccines, annual incremental costs of the three introductions amounted to US$ 23 per child in the birth cohort. It led to a cost increase of 38%, resulting in total immunisation programme costs of US$ 52.9 million in 2014, equivalent to US$ 102 per penta3 child. This is comparable to US$ 132 per penta3 child in Honduras, where PCV, RV and MSD have also been introduced [37].

Cold chain investments may be essential for new vaccines, and have been a major focus of cost studies of earlier new vaccine introductions [3]. However, in Zambia the new equipment only

Fig. 2. Actual and predicted Government health and immunisation expenditures per capita, 2008–2022. Note: From 2017 onwards, Government health expenditures are predicted using an assumption of 10% annual, nominal increase, equivalent to approximately 5% in real terms. The exchange rate between the Kwacha and the US$ is assumed constant at 8.1 between 2015 and 2022.

Fig. 3. Effect of new vaccine introduction on immunisation programme costs in Zambia. For Government health expenditures, values for 2017 and onwards are predictions based on assumptions.
represented 1% of incremental costs over time. Hence, while the ‘one-time’ costs are a substantial up-front investment, they are less important when spread over their expected lifetime.

Government health expenditures have fluctuated since 2008. Zambia experienced a serious economic situation in 2015. The annual economic growth rate declined from an average of 7% since 2010 to 3.4% in 2015 [38], partly caused by a drastic drop in the international copper price, Zambia’s main export earner [39]. It is consequently challenging to predict whether or by how much real government health expenditures will increase in coming years. Moreover, wide fluctuations of the Kwacha increase uncertainty. The average exchange rate to the USS was 4.79 Kwacha in 2011. In 2012, 2013 and 2014, the rates were 5.18, 5.35 and 6.12, respectively [13]. However, in 2015, the average rate was 8.56 and it reached 10.90 by the end of December, making the Kwacha that year’s worst performing currency against the USS [13,38].

Immunisation is projected to comprise 5–10% of government health expenditures in 2022, compared to 6% in 2014. The proportion depends on the extent real government health expenditures increases and assuming no further deterioration in the exchange rate. Even though there are no benchmarks for optimal spending on immunisation, these proportions must be considered relatively high. Projected vaccine and injection equipment costs of 3–6% of non-personnel health spending are also higher proportions than those reported as potentially challenging in other countries [12,40].

Numerous studies from sub-Saharan Africa have shown substantial health impacts and cost-effectiveness of PCV, RV and MSD [41–43]. There is thus little doubt that these vaccines are a sound investment in population health, but substantial increases in domestic financing for vaccines are necessary to ensure sustainability. Zambia funded 83% of immunisation programme costs in 2011 and has continued to increase its contribution, showing strong commitment [6]. Increasing resources to health or improving efficiency of services can potentially create fiscal space. However, it is a substantial challenge to achieve reallocations of the magnitude required for the multiple new vaccines and increased provisions to health can be expected to be difficult given the economic context. If increasing provisions to vaccines inadvertently crowd out funding of other items, such as transport for supervision and outreach, this could damage overall immunisation performance. Hence, all sustainability options require advocacy and responsive planning to reinforce the focus of government and partners on ensuring optimal transition.

Acknowledgments

This study was supported by two separate grants from the Bill & Melinda Gates Foundation to the Center for Infectious Disease Research in Zambia and to Health and Development Africa in South Africa.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.06.050.

References

[1] Saxenian H, Cornejo S, Thorien R, Hecht R, Schwab N. An analysis of how the GAVI Alliance and low- and middle-income countries can share costs of new vaccines. Health Aff 2011;30(6):1122–33.
[2] Chilenga R, Rudd C, Bolton C, Guffey B, Masumbu PK, Stringer J. Successes, challenges and lessons learned in accelerating introduction of rotavirus immunisation in Zambia. World J Vaccines 2015;5:43–53.
[3] Griffiths UK, Korczak VS, Ayalew D, Yigzaw A. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 2005;23(9):1425–32.
[4] Burchett HED, Mounier-Jack S, Griffiths UK, Bielik R, Ongolo-Zogo P, Chavez E. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries. Health Policy Plan 2012;27:ii5–ii16.
[5] Institute of Health Metrics and Evaluation. GAVI full country evaluation 2013 process evaluation of pneumococcal vaccine introduction in Mozambique, Uganda, and Zambia; 2014.
[6] Schur C, Chansa C, Mandia E, Guthrie TA, Banda S, Nombewu Z, et al. Cost analysis of routine immunisation in Zambia. Vaccine 2015;33(1 Suppl 1):A47–52.
[7] Brenzel L, Young D, Walker DG. Costs and financing of routine immunization: approaches and selected findings of a multi-country study (EPIC). Vaccine 2015;33(1 Suppl 1):A13–20.
[8] Gavi. Country eligibility policy; 2015.
[9] Gavi. Guidelines for applications. New and underused vaccines support 2013. Geneva; 2013.
[10] Norwegian Institute of Public Health. Evaluation of the GAVI Alliance Co-financing policy; 2014.
[11] Doctors without borders. The right shot: bringing down barriers to affordable and adapted vaccines, 2nd ed.; 2015.
[12] Saxenian H, Hecht R, Kaddar M, Schmitt S, Ryckman T, Cornejo S. Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries. Health Policy Plan 2015;30(2):197–205.
[13] GMA. Currency historical rates. <http://www.oanda.com/currency/historical-rates>.
[14] International Monetary Fund. Zambia: gross domestic product, deflator; 2015.
[15] WHO: WHO guide for standardization of economic evaluation of immunisation programmes. Geneva: Immunization, Vaccines and Biologicals Department, vol. WHO/IMI/08.14; 2008.
[16] WHO vaccine-preventable diseases. monitoring system. Global summary; 2015. <http://apps.who.int/immunization_monitoring/globalsummary/countycountries?country=5B&5D=565B&5D=2M8&commit=0>.
[17] Central Statistical Office. 2010 census of population and housing. Population and Demographic Projections 2011–2035. Lusaka, Zambia; 2013.
[18] Gavi. Supplementary guidelines for rotavirus vaccine applications in 2015. New and underused vaccines support; 2014.
[19] Product menu for vaccines supplied by Unicef for the GAVI Alliance. <http://www.unicef.org/ supply/index_gavi.html>.
[20] Hargreaves J, Greenwood B, Clift C, Goel A, Roemer-Mahler A, Smith R, et al. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. Lancet 2011;378(9806):1885–93.
[21] Vaccine price commitments from manufacturers. <http://www.gavi.org/search?searchText=vaccine+price>.
[22] Ministry of Health. Comprehensive multi-year plan 2011–2015. Lusaka; 2011.
[23] Ministry of Health. Zambia vaccine cold chain scale-up strategy. Lusaka; 2011.
[24] Immunization standards – Measles (10 dose vial). <http://www.who.int/immunization_standards/vaccine_quality/PQ_223_measles_10dose_gpomp/en/index.html>.
[25] Vaccine volume calculator. <http://www.who.int/immunization_programmes_systems/supply_chain/resources/tools/en/index4.html>.
[26] Product Information Sheet (PS) resources. <http://www.who.int/immunization_standards/vaccine_quality/ps/en>.
[27] WHO. Comprehensive EPI, post introduction of new vaccine evaluation and in-depth surveillance review. Republic of Zambia. Lusaka; 2014.
[28] All countries commitments and disbursements. <http://www.gavi.org/country/afghanistan>.
[29] International Monetary Fund. World Economic Outlook Database; 2015.
[30] Gavi. Co-financing policy, vol. Version 2.0. Geneva; 2015.
[31] Government of Republic of Zambia. Estimates of revenue and expenditure for the year 1st January 2014 to 31st December 2014. Lusaka: Government Printers; 2014.
[32] Government of Republic of Zambia. Estimates of revenue and expenditure for the year 1st January 2015 to 31st December 2015. Lusaka: Government Printers; 2015.
[33] Government of Republic of Zambia. 2015–2017 Medium term expenditure framework and the 2015 budget: Green Paper. Lusaka: Ministry of Finance; 2015.
[34] Le Gargasson JB, Nyonator FK, Adibo M, Gessner BD, Colombini A. Costs of routine immunization and the introduction of new and underutilized vaccines in Ghana. Vaccine 2015;33(Suppl 1):A40–6.
[35] Usuf E, Mackenzie G, Lowe-Jallow Y, Boye B, Atherly D, Suratadeche C, et al. Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions. Vaccine 2014;32(17):1975–81.
[36] Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C, Kayonga C, et al. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. Vaccine 2015;33(31):7357–63.
[37] Januzzi CB, Castaneda-Ojuela C, Molina Anguera IJ, Felix Garcia AC, Mendoza L, Diaz Y, et al. Examining the cost of delivering routine immunization in Honduras. Vaccine 2015;33(1 Suppl 1):A53–9.
[38] Bloomberg Business. Once Feted Zambia now snubbed as power cuts Worsen Crisis. Bloomberg Business; 2015.
[39] World Bank: Zambia Economic Brief: Powering the Zambian Economy, vol. 6. Washington; 2015.

[40] Blecher MS, Meheus F, Kollipara A, Hecht R, Cameron NA, Pillay Y, et al. Financing vaccinations – the South African experience. Vaccine 2012;30(Suppl 3):C79–86.

[41] Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, et al. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS ONE 2013;8(6):e67324.

[42] Abbott C, Tiede B, Armah G, Mahmoud A. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. Vaccine 2012;30(15):2582–7.

[43] Verguet S, Jassat W, Bertram MY, Tollman SM, Murray CJ, Jamison DT, et al. Supplementary immunization activities (SIAs) in South Africa: comprehensive economic evaluation of an integrated child health delivery platform. Glob Health Action 2013;6:1–9.